What is BioMarin Pharmaceutical?
BioMarin Pharmaceutical is a rare disease biotechnology company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- Rare disease biotechnology
- Headquarters
- San Rafael, CA
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: BMRN
What is BioMarin Pharmaceutical?
BioMarin Pharmaceutical is a rare disease biotechnology company headquartered in San Rafael, CA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
BioMarin Pharmaceutical is a rare disease biotechnology company headquartered in San Rafael, CA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, BioMarin Pharmaceutical should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does BioMarin Pharmaceutical offer?
BioMarin Pharmaceutical's profile centers on Rare disease medicines, Enzyme replacement therapies, Gene therapy, Clinical pipeline.
- Rare disease medicines· Rare disease biotechnology
- Enzyme replacement therapies· Rare disease biotechnology
- Gene therapy· Rare disease biotechnology
- Clinical pipeline· Rare disease biotechnology
- Commercial medicines· Rare disease biotechnology
- Genetic diseases· Rare disease biotechnology
How does BioMarin Pharmaceutical make money?
BioMarin Pharmaceutical makes money through commercial activity tied to rare disease biotechnology.
BioMarin Pharmaceutical monetizes through the model common to rare disease biotechnology: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads BioMarin Pharmaceutical?
BioMarin Pharmaceutical's named executives should be verified on the official leadership or investor-relations page before outreach.
- BioMarin Pharmaceutical executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- BioMarin Pharmaceutical finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- BioMarin Pharmaceutical operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact BioMarin Pharmaceutical's leadership?
BioMarin Pharmaceutical should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.biomarin.com- BioMarin Pharmaceutical investor relationsInvestor relations / corporate contactcontact via https://www.biomarin.com
- BioMarin Pharmaceutical sales or partnershipsCommercial contact routecontact via https://www.biomarin.com
- BioMarin Pharmaceutical media relationsMedia or communications contact routecontact via https://www.biomarin.com
How is BioMarin Pharmaceutical funded?
BioMarin Pharmaceutical's current status is Public company; Nasdaq: BMRN.
BioMarin Pharmaceutical's capital profile is best understood through its current public-company status: Public company; Nasdaq: BMRN. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did BioMarin Pharmaceutical get here?
BioMarin Pharmaceutical's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingBioMarin Pharmaceutical is foundedThe company begins building in rare disease biotechnology.
- Scale-upCommercial footprint expandsBioMarin Pharmaceutical broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: BMRNPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are BioMarin Pharmaceutical's competitors?
BioMarin Pharmaceutical competes with larger incumbents and focused specialists in rare disease biotechnology.
BioMarin Pharmaceutical — frequently asked questions
